News headlines about Mirna Therapeutics (NASDAQ:MIRN) have been trending somewhat positive this week, Alpha One Sentiment reports. The research group, a unit of Accern, identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mirna Therapeutics earned a news sentiment score of 0.12 on Alpha One’s scale. Alpha One also gave media stories about the biotechnology company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the company’s share price in the near term.

Insider Buying and Selling by Quarter for Mirna Therapeutics (NASDAQ:MIRN)

Shares of Mirna Therapeutics (NASDAQ:MIRN) traded down 0.6733% during mid-day trading on Friday, reaching $1.4899. The company’s stock had a trading volume of 52,410 shares. Mirna Therapeutics has a 52-week low of $1.12 and a 52-week high of $4.74. The company has a 50-day moving average price of $1.67 and a 200 day moving average price of $1.94. The company’s market cap is $31.07 million.

Separately, Cantor Fitzgerald reiterated a “hold” rating and issued a $2.00 price objective on shares of Mirna Therapeutics in a research report on Thursday, April 13th. Six equities research analysts have rated the stock with a hold rating, The company currently has an average rating of “Hold” and a consensus target price of $3.63.

COPYRIGHT VIOLATION NOTICE: “Mirna Therapeutics (MIRN) Given News Impact Score of 0.12” was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/mirna-therapeutics-mirn-given-news-impact-score-of-0-12/1372770.html.

About Mirna Therapeutics

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.